<DOC>
	<DOCNO>NCT00262730</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . Biological therapy , poly ICLC , may stimulate immune system different way stop tumor cell grow . Giving poly ICLC radiation therapy temozolomide may stop remain tumor cell grow . PURPOSE : This phase II trial study well give radiation therapy together temozolomide follow temozolomide poly ICLC work treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Radiation Therapy Temozolomide Followed Temozolomide Poly ICLC Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate safety efficacy radiation plus low-dose temozolomide follow adjuvant temozolomide intramuscular poly ICLC adult patient newly diagnose glioblastoma multiforme . Secondary - Estimate frequency toxicity associate treatment regimen . OUTLINE : This open-label , multicenter study . - Induction chemoradiotherapy : Patients undergo radiotherapy daily , 5 day week , 6 week . During 6 week , patient also receive oral temozolomide daily . Four week later , patient evaluate disease progression . Patients progressive disease remove study . Patients progressive disease proceed maintenance therapy . - Maintenance therapy : Patients receive oral temozolomide daily day 1-5 ( week 1 ) . Patients also receive poly ICLC intramuscularly three time week week 2-8 . Courses repeat every 9 week absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 2 month survival . PROJECTED ACCRUAL : A total 96 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm supratentorial grade IV astrocytoma ( glioblastoma multiforme ) biopsy resection within past 3 month PATIENT CHARACTERISTICS : Karnofsky performance status ≥ 60 % Absolute neutrophil count ≥ 1500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 mg/dL Transaminases ≤ 4 time upper limit institutional normal Creatinine ≤ 1.7 mg/dL Not pregnant breastfeed Patients must agree follow acceptable birth control method avoid conception Negative pregnancy test Patients must Mini Mental State Exam score ≥ 15 No serious concurrent infection medical illness would jeopardize ability patient receive treatment outline protocol reasonable safety Patients concurrent prior malignancy ineligible unless patient curatively treat carcinomainsitu basal cell carcinoma skin Patients free disease ( prior malignancy ) ≥ five year eligible study Patients require ongoing therapy psychosis antipsychotic medication time enrollment ineligible PRIOR CONCURRENT THERAPY : Patients must receive prior radiation therapy , chemotherapy , immunotherapy therapy biologic agent ( include immunotoxins , immunoconjugates , antisense , peptide receptor antagonist , interferon , interleukin , TIL , LAK gene therapy ) , hormonal therapy brain tumor Prior glucocorticoid therapy allow Patients must willing forego cytotoxic noncytotoxic drug therapy tumor treat poly ICLC plus temozolomide protocol No concurrent therapy tumor ( i.e. , chemotherapeutics investigational agent ) Patients receive prior Gliadel wafer eligible study No concurrent prophylactic filgrastim ( GCSF ) No concurrent electron , particle , implant , stereotactic radiosurgery boost</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>